When Eli Lilly announced plans to submit a Biologics License Application, rather than a New Drug Application, for retatrutide in early 2027, it highlighted a regulatory distinction that shapes how peptide drugs are reviewed, and eventually how they can be copied once their exclusivity expires. Semaglutide and tirzepatide were both approved through the New Drug Application pathway. Retatrutide is expected to go through a different one. The difference is not just paperwork.
Two Pathways, Two Legal Frameworks
A New Drug Application (NDA) is reviewed under the Federal Food, Drug, and Cosmetic Act and is the traditional route for chemically synthesized drugs, including most small-molecule medications and many simpler synthetic peptides. A Biologics License Application (BLA) is reviewed under the Public Health Service Act and is the pathway for "biological products," a category that includes vaccines, gene therapies, blood products, and larger or more structurally complex protein-based therapeutics.
Where the FDA Draws the Line for Peptides
Because many modern drugs are peptides, chains of amino acids, of varying size and complexity, the FDA published a specific rule to reduce case-by-case ambiguity about which pathway applies. Under that rule, an alpha amino acid polymer with a defined sequence larger than 40 amino acids is generally treated as a "protein," and therefore a biological product reviewed as a BLA. A chemically synthesized polypeptide between 40 and 100 amino acids occupies its own defined category under the rule, which is part of why some synthetic peptides in that size range, and simpler ones under 40 amino acids, have continued to be reviewed as traditional drugs via the NDA pathway rather than automatically becoming biologics. Semaglutide and tirzepatide, both relatively short chemically synthesized peptides, fall on the drug side of that line. Larger, more structurally complex constructs, including multi-receptor agonists and molecules built with additional protein domains, are more likely to fall on the biologic side, which appears to be the case for retatrutide.
Why This Distinction Outlasts a Drug's Initial Approval
The pathway a drug is approved through determines what kind of competition it can eventually face. A drug approved via an NDA can, once patents and exclusivity expire, face a true generic, an identical copy approved through an abbreviated process that relies on the original safety and efficacy data. A biologic approved via a BLA cannot get a true generic at all; the best a competitor can offer is a biosimilar, a highly similar but not identical product approved through its own distinct and generally more demanding regulatory pathway, in part because larger, more complex molecules are inherently harder to reproduce with molecular precision than a short synthetic peptide.
Why This Matters for the Future GLP-1 Landscape
This is directly relevant to the ongoing question of when lower-cost competition might reach the broader GLP-1 and multi-agonist drug market, a topic covered elsewhere on this site in the context of the FDA's recent workshop on generic GLP-1 drugs and current semaglutide and tirzepatide patent timelines. If next-generation drugs like retatrutide are approved as biologics rather than traditional drugs, any eventual cost competition for them would likely come from biosimilars rather than conventional generics, a different, generally slower and more expensive pathway to bring to market. In other words, the regulatory category a drug is approved under today has real consequences for how, and how quickly, cheaper versions might become available years from now.